Core Discrete Event Simulation Model for the Evaluation of Health Care Technologies in Major Depressive Disorder

被引:11
|
作者
Vataire, Anne-Lise [1 ]
Aballea, Samuel [1 ]
Antonanzas, Fernando [2 ]
Hakkaart-van Roijen, Leona [3 ]
Lam, Raymond W. [4 ]
McCrone, Paul [5 ]
Persson, Ulf [6 ]
Toumi, Mondher [7 ]
机构
[1] Creat Ceut, F-75008 Paris, France
[2] Univ La Rioja, Logrono, Spain
[3] Erasmus Univ, Rotterdam, Netherlands
[4] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[5] Kings Coll London, London, England
[6] Swedish Inst Hlth Econ, Lund, Sweden
[7] Univ Lyon, Lyon, France
关键词
antidepressants; cost-effectiveness; depression; discrete event simulation; RESIDUAL SYMPTOMS; IMPACT; REMISSION; CITALOPRAM; COSTS; RISK;
D O I
10.1016/j.jval.2013.11.012
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: A review of existing economic models in major depressive disorder (MDD) highlighted the need for models with longer time horizons that also account for heterogeneity in treatment pathways between patients. A core discrete event simulation model was developed to estimate health and cost outcomes associated with alternative treatment strategies. Methods: This model simulated short- and long-term clinical events (partial response, remission, relapse, recovery, and recurrence), adverse events, and treatment changes (titration, switch, addition, and discontinuation) over up to 5 years. Several treatment pathways were defined on the basis of fictitious antidepressants with three levels of efficacy, tolerability, and price (low, medium, and high) from first line to third line. The model was populated with input data from the literature for the UK setting. Model outputs include time in different health states, quality-adjusted life-years (QALYs), and costs from National Health Service and societal perspectives. The codes are open source. Results: Predicted costs and QALYs from this model are within the range of results from previous economic evaluations. The largest cost components from the payer perspective were physician visits and hospitalizations. Key parameters driving the predicted costs and QALYs were utility values, effectiveness, and frequency of physician visits. Differences in QALYs and costs between two strategies with different effectiveness increased approximately twofold when the time horizon increased from 1 to 5 years. Conclusion: The discrete event simulation model can provide a more comprehensive evaluation of different therapeutic options in MDD, compared with existing Markov models, and can be used to compare a wide range of health care technologies in various groups of patients with MUD.
引用
收藏
页码:183 / 195
页数:13
相关论文
共 50 条
  • [21] A Discrete-Event Simulation Model of Hospital Patient Flow Following Major Earthquakes
    Basaglia, Alberto
    Spacone, Enrico D.
    van de Lindt, John W.
    Kirsch, Thomas D.
    INTERNATIONAL JOURNAL OF DISASTER RISK REDUCTION, 2022, 71
  • [22] Evaluation of Lifetime Trauma Exposure and Physical Health in Women With Posttraumatic Stress Disorder or Major Depressive Disorder
    Dennis, Michelle F.
    Flood, Amanda M.
    Reynolds, Victoria
    Araujo, Gustavo
    Clancy, Carolina P.
    Barefoot, John C.
    Beckham, Jean C.
    VIOLENCE AGAINST WOMEN, 2009, 15 (05) : 618 - 627
  • [23] Exhaustion Disorder in Primary Care: A Comparison With Major Depressive Disorder and Adjustment Disorder
    Sennerstam, Victoria
    Hedman-Lagerlof, Erik
    Nilsonne, Gustav
    Lekander, Mats
    Ruck, Christian
    Wallert, John
    Axelsson, Erland
    Lindsater, Elin
    SCANDINAVIAN JOURNAL OF PSYCHOLOGY, 2025, 66 (03) : 315 - 326
  • [24] Major Depressive Disorder in Primary Care: Strategies for Identification
    Trivedi, Madhukar H.
    JOURNAL OF CLINICAL PSYCHIATRY, 2020, 81 (02)
  • [25] A discrete event simulation model to evaluate the treatment pathways of patients with cataract in the United Kingdom
    Demir, Eren
    Southern, David
    Rashid, Syed
    Lebcir, Reda
    BMC HEALTH SERVICES RESEARCH, 2018, 18
  • [26] An empirical comparison of Markov cohort modeling and discrete event simulation in a capacity-constrained health care setting
    Standfield, L. B.
    Comans, T. A.
    Scuffham, P. A.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2017, 18 (01) : 33 - 47
  • [27] Neurostimulation therapies in major depressive disorder: A decision-analytic model
    Teng, Monica
    Khoo, Ai Leng
    Zhao, Ying Jiao
    Abdin, Edimansyah
    Mok, Yee Ming
    Lim, Boon Peng
    Tor, Phern Chern
    EARLY INTERVENTION IN PSYCHIATRY, 2021, 15 (06) : 1531 - 1541
  • [28] Evaluation of periodontitis in hospital outpatients with major depressive disorder
    Solis, A. C. O.
    Marques, A. H.
    Pannuti, C. M.
    Lotufo, R. F. M.
    Lotufo-Neto, F.
    JOURNAL OF PERIODONTAL RESEARCH, 2014, 49 (01) : 77 - 84
  • [29] Evidence based review of escitalopram in treating major depressive disorder in primary care
    Einarson, TR
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2004, 19 (05) : 305 - 310
  • [30] Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment
    Broder, Michael S.
    Greene, Mallik
    Yan, Tingjian
    Chang, Eunice
    Hartry, Ann
    Yermilov, Irina
    CLINICAL THERAPEUTICS, 2019, 41 (02) : 221 - 232